Cargando…
The efficacy of anti–TNF-α agents in the treatment of juvenile idiopathic arthritis-associated uveitis in a pediatric cohort
PURPOSE: Biologic therapy has shown promising control in children with often intractable juvenile idiopathic arthritis (JIA)-associated uveitis (JIA-U). METHODS: This is a retrospective cohort study of 35 eyes of 35 children who received biologics for JIA-U. Pretreatment and posttreatment data (at 3...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391364/ https://www.ncbi.nlm.nih.gov/pubmed/37202943 http://dx.doi.org/10.4103/IJO.IJO_2548_22 |
_version_ | 1785082688473923584 |
---|---|
author | ElMohsen, Mai Nasser Abd Hassan, Lameece Moustafa Youssef, Maha Mohamed Naga, Shereen H Aboul |
author_facet | ElMohsen, Mai Nasser Abd Hassan, Lameece Moustafa Youssef, Maha Mohamed Naga, Shereen H Aboul |
author_sort | ElMohsen, Mai Nasser Abd |
collection | PubMed |
description | PURPOSE: Biologic therapy has shown promising control in children with often intractable juvenile idiopathic arthritis (JIA)-associated uveitis (JIA-U). METHODS: This is a retrospective cohort study of 35 eyes of 35 children who received biologics for JIA-U. Pretreatment and posttreatment data (at 3, 6, 9, 12, 18, 24, and >24 months) were analyzed to determine functional success (stable/improved visual acuity), quiescence success (≤0.5 cells in the anterior chamber), complete steroid success (termination of systemic, periocular therapy and decreased topical drops to ≤2/day) or systemic steroid success (termination of systemic steroids only), and complete success (all of the above). RESULTS: This study included 35 eyes up to 12 months and 21 eyes beyond 24 months. Steroid-sparing, functional, and quiescence success showed a rate of success of 52.43%, 77%, and 91%, respectively, at 12 months and 66.67%, 85.7%, and 76.2%, respectively, beyond 24 months. Complete success was 34.29% at 12 months, peaking at 18 months (65.62%) and reached 57.14% beyond 24 months. In their final follow-up, the best corrected visual acuity (BCVA) remained the same in 45.71%, improved in 37.14%, and worsened in 17.14% children. CONCLUSION: Biologic therapy is effective in JIA-U, especially in termination of systemic steroids, stabilization of vision, and maintaining quiescence. |
format | Online Article Text |
id | pubmed-10391364 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-103913642023-08-02 The efficacy of anti–TNF-α agents in the treatment of juvenile idiopathic arthritis-associated uveitis in a pediatric cohort ElMohsen, Mai Nasser Abd Hassan, Lameece Moustafa Youssef, Maha Mohamed Naga, Shereen H Aboul Indian J Ophthalmol Original Article PURPOSE: Biologic therapy has shown promising control in children with often intractable juvenile idiopathic arthritis (JIA)-associated uveitis (JIA-U). METHODS: This is a retrospective cohort study of 35 eyes of 35 children who received biologics for JIA-U. Pretreatment and posttreatment data (at 3, 6, 9, 12, 18, 24, and >24 months) were analyzed to determine functional success (stable/improved visual acuity), quiescence success (≤0.5 cells in the anterior chamber), complete steroid success (termination of systemic, periocular therapy and decreased topical drops to ≤2/day) or systemic steroid success (termination of systemic steroids only), and complete success (all of the above). RESULTS: This study included 35 eyes up to 12 months and 21 eyes beyond 24 months. Steroid-sparing, functional, and quiescence success showed a rate of success of 52.43%, 77%, and 91%, respectively, at 12 months and 66.67%, 85.7%, and 76.2%, respectively, beyond 24 months. Complete success was 34.29% at 12 months, peaking at 18 months (65.62%) and reached 57.14% beyond 24 months. In their final follow-up, the best corrected visual acuity (BCVA) remained the same in 45.71%, improved in 37.14%, and worsened in 17.14% children. CONCLUSION: Biologic therapy is effective in JIA-U, especially in termination of systemic steroids, stabilization of vision, and maintaining quiescence. Wolters Kluwer - Medknow 2023-05 2023-05-17 /pmc/articles/PMC10391364/ /pubmed/37202943 http://dx.doi.org/10.4103/IJO.IJO_2548_22 Text en Copyright: © 2023 Indian Journal of Ophthalmology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article ElMohsen, Mai Nasser Abd Hassan, Lameece Moustafa Youssef, Maha Mohamed Naga, Shereen H Aboul The efficacy of anti–TNF-α agents in the treatment of juvenile idiopathic arthritis-associated uveitis in a pediatric cohort |
title | The efficacy of anti–TNF-α agents in the treatment of juvenile idiopathic arthritis-associated uveitis in a pediatric cohort |
title_full | The efficacy of anti–TNF-α agents in the treatment of juvenile idiopathic arthritis-associated uveitis in a pediatric cohort |
title_fullStr | The efficacy of anti–TNF-α agents in the treatment of juvenile idiopathic arthritis-associated uveitis in a pediatric cohort |
title_full_unstemmed | The efficacy of anti–TNF-α agents in the treatment of juvenile idiopathic arthritis-associated uveitis in a pediatric cohort |
title_short | The efficacy of anti–TNF-α agents in the treatment of juvenile idiopathic arthritis-associated uveitis in a pediatric cohort |
title_sort | efficacy of anti–tnf-α agents in the treatment of juvenile idiopathic arthritis-associated uveitis in a pediatric cohort |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391364/ https://www.ncbi.nlm.nih.gov/pubmed/37202943 http://dx.doi.org/10.4103/IJO.IJO_2548_22 |
work_keys_str_mv | AT elmohsenmainasserabd theefficacyofantitnfaagentsinthetreatmentofjuvenileidiopathicarthritisassociateduveitisinapediatriccohort AT hassanlameecemoustafa theefficacyofantitnfaagentsinthetreatmentofjuvenileidiopathicarthritisassociateduveitisinapediatriccohort AT youssefmahamohamed theefficacyofantitnfaagentsinthetreatmentofjuvenileidiopathicarthritisassociateduveitisinapediatriccohort AT nagashereenhaboul theefficacyofantitnfaagentsinthetreatmentofjuvenileidiopathicarthritisassociateduveitisinapediatriccohort AT elmohsenmainasserabd efficacyofantitnfaagentsinthetreatmentofjuvenileidiopathicarthritisassociateduveitisinapediatriccohort AT hassanlameecemoustafa efficacyofantitnfaagentsinthetreatmentofjuvenileidiopathicarthritisassociateduveitisinapediatriccohort AT youssefmahamohamed efficacyofantitnfaagentsinthetreatmentofjuvenileidiopathicarthritisassociateduveitisinapediatriccohort AT nagashereenhaboul efficacyofantitnfaagentsinthetreatmentofjuvenileidiopathicarthritisassociateduveitisinapediatriccohort |